A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Public ClinicalTrials.gov record NCT06483334. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04C
Study identification
- NCT ID
- NCT06483334
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 38 participants
Conditions and interventions
Interventions
- Enfortumab Vedotin Biological
- Pembrolizumab Biological
- Sacituzumab tirumotecan Biological
- Supportive care measures Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 16, 2024
- Primary completion
- Mar 30, 2028
- Completion
- Mar 30, 2028
- Last update posted
- Feb 17, 2026
2024 – 2028
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco HDFCCC ( Site 4044) | San Francisco | California | 94158 | — |
| University of Chicago Medical Center ( Site 4037) | Chicago | Illinois | 60637 | — |
| Indiana University Melvin and Bren Simon Cancer Center ( Site 4011) | Indianapolis | Indiana | 46202 | — |
| Dana-Farber Cancer Institute ( Site 4047) | Boston | Massachusetts | 02115 | — |
| Siteman Cancer Center ( Site 4038) | St Louis | Missouri | 63108 | — |
| Icahn School of Medicine at Mount Sinai ( Site 4018) | New York | New York | 10029 | — |
| Cleveland Clinic-Taussig Cancer Center ( Site 4036) | Cleveland | Ohio | 44195 | — |
| Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 4041) | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06483334, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2026 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06483334 live on ClinicalTrials.gov.